CompletedPhase 2ACTRN12607000190404

Extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diease

A multicentre phase II trial of extended treatment with rituximab to assess complete remission rate in patients with B-cell post-transplant lymphoproliferative diease

Sponsor

Alberto Fernández de Sevilla on behalf of the Catalan Institute of Oncology

Enrollment

40 participants

Start Date

Nov 1, 2000

Study Type

Interventional

Conditions

Post solid organ transplant lymphoproliferative disease

Summary

Not randomized trial of treatment with standard doses of rituximab for untreated B-cell lymphoproliferative disease. Treatment regimen was adapted to early response, patients received 4 to 8 courses of rituximab.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study evaluates extended treatment with rituximab for patients with B-cell non-Hodgkin lymphoma who have already responded to initial therapy. This study is open to both men and women aged 18 and older. Participation involves receiving additional rituximab infusions and regular monitoring of your blood counts and health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Treatment with 4 courses, one per week during 4 weeks, of intravenous Rituximab at a dose of 375 mg/m2 (standard doses). Patients who progressed were excluded from the study. Patients in complete rem

Treatment with 4 courses, one per week during 4 weeks, of intravenous Rituximab at a dose of 375 mg/m2 (standard doses). Patients who progressed were excluded from the study. Patients in complete remission after 4 courses were followed without further treatment. Participants in complete remission after 4 courses were followed up every 3 monts during 2 years or until progression. Patients with partial response received another 4 weekly courses of rituximab at the same doses. Participants in complete remission after 8 courses were followed up every 3 monts during 2 years or until progression

Locations(1)

Spain

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000190404